Baxter’s back into the black after 12 percent sales bump
Baxter International Inc. (NYSE:BAX) posted net income of $577 million, or 98 cents per diluted share, on sales of $3.3 billion during the three months ended March 31. That compares with a loss of $60 million, or 11 cents per diluted share, on sales of $2.9 billion during the same period last year.
Read more
C. R. Bard’s Q1 income rises 9 percent
C. R. Bard Inc. (NYSE:BCR) posted net earnings of $131.9 million, or $1.49 per diluted share, on revenue of $700.3 million during the three months ended March 31. That compares with net earnings of $121.2 million, or $1.24 per diluted share, on revenue of $650.8 million during the same period last year.
Read more
NeoGenomics reports mixed Q1
NeoGenomics Inc. (OTC:NGNM) reported losses of $893,000, or 2 cents per diluted share, on revenue of $8.8 million during the three months ended March 31. That compares with losses of $750,000, or 2 cents per diluted share, on revenue of $8.4 million during the same period last year.
Read more
IDEXX profits rise after healthy sales bump
IDEXX Laboratories Inc. (NSDQ:IDXX) posted a profit of $36.6 million, or 62 cents per diluted share, on sales of $292.7 million during the three months ended March 31. That compares with profits of $33.0 million, or 55 per diluted share, on sales of $268.5 million during the same period last year.
Read more
Merit Medical sales leap 28 percent
Merit Medical Systems Inc. (NSDQ:MMSI) reported profits of $6.6 million, or 23 cents per diluted share, on revenue of $86.6 million during the three months ended March 31. That compares with profits of $4.5 million, or 16 cents per diluted share, on revenue of $67.4 million during the same period last year.
Read more